Clinical Trial Update: Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update describing pharmacokinetic and pharmacodynamic study of AMX0035 in ALS patients (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• AMX0035 (sodium phenylbutyrate and tauroursodeoxycholic acid)

Snippet

Sponsor: Amylyx Pharmaceuticals Inc. | Conditions: ALS | Phase 1, Phase 2 | Status: UNKNOWN